Emma Reeve Sells 7,333 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Emma Reeve sold 7,333 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $74.50, for a total value of $546,308.50. Following the transaction, the director owned 6,666 shares of the company’s stock, valued at approximately $496,617. This trade represents a 52.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Emma Reeve also recently made the following trade(s):

• On Thursday, October 30th, Emma Reeve sold 15,666 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.50, for a total transaction of $1,088,787.00.
• On Friday, October 3rd, Emma Reeve sold 25,562 shares of PTC Therapeutics stock. The stock was sold at an average price of $65.96, for a total transaction of $1,686,069.52.
• On Thursday, September 11th, Emma Reeve sold 15,705 shares of PTC Therapeutics stock. The stock was sold at an average price of $59.50, for a total transaction of $934,447.50.

PTC Therapeutics Price Performance

Shares of PTCT stock opened at $75.30 on Friday. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $76.80. The company’s fifty day moving average price is $65.29 and its 200-day moving average price is $54.50. The company has a market capitalization of $6.05 billion, a price-to-earnings ratio of 10.80 and a beta of 0.60.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The company had revenue of $211.01 million during the quarter, compared to the consensus estimate of $177.42 million. During the same quarter in the prior year, the firm posted ($1.39) EPS. PTC Therapeutics’s quarterly revenue was up 7.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PTCT has been the subject of several research analyst reports. Bank of America cut their target price on PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating for the company in a research report on Wednesday, August 20th. TD Cowen upped their price target on PTC Therapeutics from $50.00 to $63.00 and gave the stock a “hold” rating in a research note on Wednesday, November 5th. Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a report on Wednesday, November 5th. Jefferies Financial Group lifted their price objective on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Finally, Barclays upped their target price on shares of PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, PTC Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $75.40.

Institutional Trading of PTC Therapeutics

A number of large investors have recently made changes to their positions in PTCT. Jefferies Financial Group Inc. purchased a new stake in shares of PTC Therapeutics during the 3rd quarter valued at about $97,252,000. Nuveen LLC bought a new stake in PTC Therapeutics during the first quarter worth approximately $51,427,000. Wellington Management Group LLP increased its stake in PTC Therapeutics by 13.2% during the first quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company’s stock worth $276,161,000 after acquiring an additional 632,049 shares during the last quarter. Hood River Capital Management LLC raised its position in PTC Therapeutics by 654.4% during the second quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock valued at $31,087,000 after purchasing an additional 552,130 shares during the period. Finally, State Street Corp lifted its stake in shares of PTC Therapeutics by 22.1% in the 2nd quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock valued at $146,347,000 after purchasing an additional 541,558 shares during the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.